Analyst Price Targets — ANGO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 4:18 pm | Yi Chen | H.C. Wainwright | $19.00 | $14.49 | TheFly | AngioDynamics price target raised to $19 from $16 at H.C. Wainwright |
| July 15, 2026 10:37 am | — | Canaccord Genuity | $20.00 | $13.00 | TheFly | AngioDynamics price target raised to $20 from $16 at Canaccord |
| October 3, 2025 11:57 am | — | Canaccord Genuity | $18.00 | $11.74 | TheFly | AngioDynamics price target raised to $18 from $17 at Canaccord |
| July 16, 2025 10:57 am | John Young | Canaccord Genuity | $17.00 | $8.72 | TheFly | AngioDynamics price target raised to $17 from $15 at Canaccord |
| October 4, 2024 6:10 am | William Plovanic | Canaccord Genuity | $12.00 | $6.10 | StreetInsider | AngioDynamics (ANGO) PT Lowered to $12 at Canaccord Genuity |
| September 20, 2024 6:50 am | Yi Chen | H.C. Wainwright | $14.00 | $7.70 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on AngioDynamics (ANGO) |
| April 5, 2024 7:15 am | Steven Lichtman | Oppenheimer | $12.00 | $6.40 | TheFly | AngioDynamics upgraded to Outperform from Perform at Oppenheimer |
| January 6, 2023 7:27 am | — | Raymond James | $22.00 | $15.48 | Benzinga | Raymond James Maintains Strong Buy on AngioDynamics, Lowers Price Target to $22 |
| July 13, 2022 7:13 am | — | Raymond James | $27.00 | $20.02 | Benzinga | Raymond James Maintains Strong Buy on AngioDynamics, Lowers Price Target to $27 |
Latest News for ANGO
AngioDynamics develops tools for minimally invasive procedures across blood flow, blocked arteries, and prostate cancer treatment. Key offerings include AlphaVac and AngioVac for clot removal, Auryon for arterial plaque, and NanoKnife for prostate cancer. After a prolonged period of stagnation, ANGO shares are finally showing signs of positive momentum.
ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.
AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript
AngioDynamics NASDAQ: ANGO reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on balancing investment in clinical programs with profitability and cash generation.
AngioDynamics (ANGO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.03 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANGO.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.